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ARTICLE
Clinical Studies
New clinical and biological insights from the international
TARGIT-A randomised trial of targeted intraoperative
radiotherapy during lumpectomy for breast cancer
Jayant S. Vaidya et al.
BACKGROUND: The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy
for breast cancer to be as effective as whole-breast external beam radiotherapy (EBRT). Here, we present further detailed analyses.
METHODS: In total, 2298 women (≥45 years, invasive ductal carcinoma ≤3.5 cm, cN0–N1) were randomised. We investigated the
impact of tumour size, grade, ER, PgR, HER2 and lymph node status on local recurrence-free survival, and of local recurrence on
distant relapse and mortality. We analysed the predictive factors for recommending supplemental EBRT after TARGIT-IORT as part of
the risk-adapted approach, using regression modelling. Non-breast cancer mortality was compared between TARGIT-IORT plus
EBRT vs. EBRT.
RESULTS: Local recurrence-free survival was no different between TARGIT-IORT and EBRT, in every tumour subgroup. Unlike in the
EBRT arm, local recurrence in the TARGIT-IORT arm was not a predictor of a higher risk of distant relapse or death. Our new
predictive tool for recommending supplemental EBRT after TARGIT-IORT is at https://targit.org.uk/addrt. Non-breast cancer
mortality was significantly lower in the TARGIT-IORT arm, even when patients received supplemental EBRT, HR 0.38 (95% CI
0.17–0.88) P= 0.0091.
CONCLUSION: TARGIT-IORT is as effective as EBRT in all subgroups. Local recurrence after TARGIT-IORT, unlike after EBRT, has a
good prognosis. TARGIT-IORT might have a beneficial abscopal effect.
TRIAL REGISTRATION: ISRCTN34086741 (21/7/2004), NCT00983684 (24/9/2009).
British Journal of Cancer https://doi.org/10.1038/s41416-021-01440-8
INTRODUCTION
Most patients with breast cancer are suitable for treatment with
breast-conserving surgery and adjuvant radiotherapy, rather than
total mastectomy. Based on the hypothesis that adjuvant radio-
therapy for women with early breast cancer could be limited to
the tumour bed and given immediately during breast-conserving
surgery (lumpectomy), we developed the concept of TARGeted
Intraoperative radioTherapy (TARGIT-IORT).1–6
TARGIT-IORT aims to achieve an accurately-positioned and rapid
form of tumour-bed irradiation, focussed on the target tissues alone,
sparing normal tissues and organs such as heart, lung, skin and
chest wall structures from unnecessary and potentially damaging
radiation treatment. We designed the TARGIT-A randomised trial to
test this concept by comparing risk-adapted TARGIT-IORT with
conventional whole-breast external beam radiotherapy over several
weeks (EBRT).3,7,8 The study received ethics approval from the Joint
University College London and University College London Hospital
committees of ethics of human research (99/0307). The accrual was
from March 2000 to June 2012. The long-term results of the trial are
described separately and show that TARGIT-IORT is as effective as
whole-breast external beam radiotherapy (EBRT) for all breast cancer
outcomes, with a significant reduction in mortality from causes
other than breast cancer.9
The trial eligibility was not confined to low-risk patients: they
needed to be 45 years or older, with invasive ductal carcinoma that
was suitable for breast conservation and preferably less than 3.5 cm
in size and unifocal on clinical examination and conventional
imaging. Having a grade 3 cancer, involved nodes or higher risk
receptor status, did not exclude the patient from participating.
Therefore, a large number of patients in each category of higher risk
were included, allowing meaningful subgroup analysis. In addition,
the follow-up of the TARGIT-A trial was long, with a large number of
patients having follow-up for at least 5 years (n= 2048) and 10 years
(n= 741). So, the number of events for local recurrences and deaths
after long-term follow-up were expected to be large enough to
assess the prognostic significance of local recurrence.
As specified in the protocol, treatment was given using a risk-
adapted approach, which meant that patients allocated to receive
TARGIT-IORT were recommended to also receive supplemental
EBRT, if they were postoperatively found to have specific
unsuspected tumour characteristics, in which case the TARGIT-
IORT served as a tumour-bed boost. The protocol specified three
such factors—an unexpected diagnosis of invasive lobular
carcinoma, presence of extensive intraductal component (>25%)
and positive margins. Pragmatically, each centre was allowed to
pre-specify such criteria and they recorded them in the ‘treatment
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policy document’ before they started recruitment. Therefore, for
an individual case, the use of supplemental EBRT depended on a
combination of several factors discussed in the post-operative
multidisciplinary team meeting (tumour board). Having known the
use of supplemental EBRT within the trial (about 20% of cases) and
with the knowledge of the tumour factors, a regression model
could be created.
This risk-adapted approach also offers an opportunity for another
type of analysis investigating the mechanism of the difference we
found in non-breast cancer mortality during the main analysis.9 One
needs to recognise that the use of supplemental EBRT after TARGIT-
IORT was prompted by specific features of the primary breast
cancer. Therefore, there should be no reason for the risk of non-
breast cancer mortality to be different between patients who
received TARGIT+ EBRT vs. those who received EBRT. Since both
groups received EBRT, and if the difference was because of EBRT
toxicity alone, there should be no difference found in non-breast
cancer mortality in this comparison.
This paper addresses four important aspects of the trial of
TARGIT-IORT vs. EBRT, in which 2298 patients were randomised
after their needle biopsy and before any surgical excision of
cancer to receive either risk-adapted TARGIT-IORT delivered
during the initial excision of cancer, or EBRT. These are: (a)
outcome as per well-recognised tumour subgroups, (b) prognostic
importance of local recurrence, (c) a predictive model for the use
of supplemental EBRT after TARGIT-IORT and (d) an exploration
seeking explanation for the differences in non-breast cancer
mortality found between the two randomised arms.
METHODS
Data from the TARGIT-A trial (n= 2298) comparing risk-adapted
TARGIT-IORT given during lumpectomy vs. EBRT were used for
these analyses.9
The TARGIT-A trial protocol (https://njl-admin.nihr.ac.uk/
document/download/2006598), including the details of eligibility,
methodology and statistical methods, sample size calculations, the
process of random allocation, has been previously described.7,8,9
Eligible patients diagnosed with invasive malignancy by needle
biopsy were randomly assigned before their surgery, in a 1:1 ratio,
to receive either a risk-adapted approach using single-dose
TARGIT-IORT or EBRT as per standard schedules over several
weeks, with randomisation blocks stratified by centre. Therefore,
the trial was a comparison of two policies—whole-breast radio-
therapy without selection vs. individualised risk-adapted radio-
therapy—in which a proportion of patients who received TARGIT-
IORT were also given supplemental EBRT if they were found to
have any pre-specified tumour factors.
The sites participating in the trial were all centres of excellence
(almost all were University teaching hospitals) with their own
routine quality assurance in place. Every patient was treated as per
the treatment guidelines and quality assurance laid down by each
of the participating radiotherapy centres. While the collection of
specific data relating to quality assurance was not mandatory, the
schedule of treatment, total dose, dose per fraction and number of
fractions for the EBRT (and the boost when given) were always
collected. In the UK, the most widely used dose-fractionation
regimen recommended during the time of the study was 40.05
Gy/15 fractions over 3 weeks, i.e., daily dose 2.67 Gy per fraction. In
the USA, the commonest recommendation was 50 Gy/25 fractions
over 5 weeks. For boost doses, institutional standards were once
again routinely employed—mostly 10 Gy/5 fractions.
The statistical analysis plan (SAP, submitted with the manu-
script) was signed off by the chair of the independent steering
committee and an independent senior statistician, before the data
were unblinded and sent to the trial statistician for analysis. It
specified the primary outcome as local recurrence-free survival.
This outcome measured the chance of a patient being alive
without local recurrence (any type of local recurrence in the
ipsilateral breast) and therefore included local recurrence or death
as events, i.e., patients who had died were not censored, which is
consistent with the DATECAN10 and STEEP11 guidelines for clinical
events to be included in the definitions of time-to-event
endpoints in randomised clinical trials assessing treatments for
breast cancer12. All analyses were by intention-to-treat as per the
randomisation arm.
Firstly, we performed a subgroup analysis for the primary
outcome of local recurrence-free survival for the tumour factors
such as size, grade, lymph node involvement, ER status, PgR status
and HER2 status.
Secondly, the concern that a difference in local recurrence
might increase long-term mortality prompted us to investigate
the assumption that local recurrence is a harbinger of distant
disease and ultimately of death. We, therefore, performed Cox
regression analysis using local recurrence as a time-dependent
covariate, and estimated its interaction for the hazards of distant
disease, breast cancer mortality in the two randomised arms. We
also assessed this for overall mortality in order to take away any
bias from the misclassification of the cause of death.
Thirdly, we prepared a regression model using established high-
risk factors to predict the use of supplemental EBRT in patients
randomised to TARGIT-IORT. Significant factors from the model
were used to create an interactive tool that would simulate how
patients were treated in the TARGIT-A trial and whether they
received supplemental EBRT. Such a tool should help clinicians
decide which patients would have received such supplemental
EBRT and enable them to translate the risk-adapted approach
used within the randomised trial into day-to-day clinical practice.
Finally, we explored the reason for the statistically significant
difference in non-breast cancer mortality already seen between
the two randomised arms. We compared non-breast cancer
mortality between those who had received TARGIT-IORT followed
by supplemental EBRT vs. EBRT. Any difference between these two
groups would be indicative of a beneficial effect of TARGIT-IORT
because both groups had received EBRT.
The first patient was randomised in March 2000, and the last in
June 2012. The reference date for completeness of follow-up was
May 2, 2018. The reference date for analysis was July 3, 2019, so
that all events in the entire population up until July 2, 2019 were
included for analysis of hazard ratios. Point estimates are given for
5 years, at which point the follow-up is complete, and hazard
ratios are estimated for the full length of the follow-up period, i.e.,
the length of time from randomisation to the date of the latest
follow-up, for each individual patient. STATA version 16.0 was
used for data compilation, validation and analysis. The chief
investigator/corresponding author and the trial statistician had
access to all data sent by the trial centre for the analysis; all
authors were responsible for the decision to submit the manu-
script. Since the last analysis, the trial oversight has been provided
by an independent steering committee, appointed by the Health
Technology Assessment Programme of the National Institute of
Health Research, Department of Health, UK.
RESULTS
In total, 1140 patients were randomised to TARGIT-IORT and 1158
to whole-breast radiotherapy. Patients were recruited from ten
countries (24.7% from UK, 65.1% Europe, 9.4% USA/Canada and
0.8% others). Supplementary Table 1 shows the characteristics of
trial patients.
As previously published,9 there was no statistically significant
difference in local recurrence-free survival (events 167 vs. 147,
hazard ratio 1.13, 95% confidence interval 0.91–1.41, P= 0.28),
distant disease-free survival (133 vs. 148 events, HR 0.88,
0.69–1.12, P= 0.30), mastectomy-free survival (170 vs. 175 events,
0.96, 0.78–1.19, P= 0.74) or breast cancer mortality (65 vs. 57
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events, HR 1.12, 0.78–1.60, P= 0.54). There was a significant
reduction in non-breast cancer mortality with TARGIT-IORT (45 vs.
74 events, HR 0.59, 0.40–0.86, P= 0.005).
In addition, no difference was found in local recurrence-free
survival when the following comparisons were made: EBRT
patients vs. TARGIT-IORT patients who received additional
EBRT (HR 1.19, 0.83–1.71, P= 0.3422) and EBRT patients vs.
TARGIT-IORT patients who did not receive additional EBRT (HR
1.12, 0.88–1.41, P= 0.3661) (Supplementary Fig. 1).
The new analysis presented in this paper examines four specific
aspects of the data accrued from this large, randomised trial.
Firstly, the difference in the primary outcome of survival without
local recurrence between TARGIT-IORT and EBRT was not
significant for any of the tumour subgroups viz pathological
tumour size, grade, ER status, PgR status, HER2 status and lymph
node status (Table 1 and Fig. 1). Prompted by comments from
reviewers, we created subgroups using combinations of factors
and performed the following analyses. The most substantial of
these include 1468 (64%) ‘lower-risk’ patients in whom the
tumours were not >2 cm, or grade 3 or ER-negative, irrespective of
age or lymph node status (59% were <65 years old and 17% were
node-positive). The remaining 830 patients (‘not-lower-risk’) would
have at least one of these risk factors.
Analysis within each of these two subgroups found no
difference in local control between the randomised arms
TARGIT-IORT vs. EBRT by intention-to-treat, (‘lower-risk’ n= 1468,
HR 1.05 (95% CI 0.77–1.44, P= 0.7450 and ‘not-lower-risk’ n= 830,
HR 1.24 95% CI 0.91– 1.70, P= 0.1715), or after excluding those
who received supplemental EBRT after TARGIT-IORT (n= 1331,
‘lower-risk’ HR 1.02 (0.73–1.43), P= 0.8859 and ‘not-lower-risk’ n=
726, HR 1.28 (0.92–1.79), P= 0.1404). Similarly, no difference was
found for the higher-risk subgroup of with triple-negative breast
cancers by intention-to-treat (n= 143, HR 0.87 (0.45–1.67), P=
0.6840) or after excluding those who received supplemental EBRT
(n= 131, HR 0.84 (0.43–1.66), P= 0.6300)), or those with HER2-
negative tumours which were either ER- or PR-negative by
intention-to-treat (n= 317, HR 1.01 (0.60–1.69), P= 0.9730), or
after excluding those who received supplemental EBRT (n= 281,
HR 1.03 (0.60–1.78), P= 0.9039). However, for those 1468 ‘lower-
risk’ patients (not > 2 cm, or grade 3 or ER-negative), overall
survival with TARGIT-IORT was 4.2% better at 12 years (TARGIT-
IORT 91.7% vs. EBRT 87.3%, HR 0.65 (95% CI 0.44–0.96), P=
0.0308). Figure 1 also shows the overall survival outcomes in each
main subgroup. The overall survival was significantly better by
4.4% (89.3 vs. 84.9%) at 12 years with TARGIT-IORT compared with
EBRT in those with grade 1 or 2 cancers, (Fig. 2, n= 1797, HR 0.72,
95% CI 0.53–0.98, P= 0.0361). We recognise of course that these
are subgroup analyses, with all the usual caveats.
Secondly, the analysis of an interaction between local
recurrence and mortality found that the prognostic significance
of local recurrence in the EBRT arm was different to that of local
recurrence in the TARGIT-IORT arm. Local recurrence in the EBRT
arm but not in the TARGIT-IORT arm predicted a higher risk of
distant disease (P value for interaction P= 0.008, Fig. 3a), breast
cancer mortality (P value for interaction P= 0.003, Fig. 3b), and
overall mortality (P value for interaction P= 0.020, Fig. 3c). This
interaction might be better appreciated when seen in terms of the
raw numbers of long-term deaths amongst those who had local
recurrence within 5 years: 3/24 (13%) died in the TARGIT-IORT vs.
7/11 (63%) died in the EBRT arm. The mean survival duration of
patients who had early local recurrence in the TARGIT arm was 8.7
years (SD 3.1) vs. EBRT 6.1 years (SD 3.3).
Thirdly, the proportion of patients who ultimately received
supplemental EBRT in addition to TARGIT-IORT for each prognostic
subgroup is given in Table 2, which also gives the local recurrence
and mortality events, cumulative incidence of local recurrence,
and local control rates as per treatment received. The regression
model (sensitivity 71%, specificity 67%, correct classification in
68% of cases) for predicting the use of supplemental EBRT in an
individual patient is available on the web and can be best
understood with direct interaction. We urge the readers to click on
the link https://targit.org.uk/addrt and input some numbers for a
Table 1. Subgroup analysis: number of events for local recurrence and deaths and point estimates for local recurrence-free survival are given for 5
years when the follow-up is complete, as per protocol.












Hazard ratio 95% confidence
interval of hazard ratio
Tumour size <=10mm 739 369 10 8 370 2 10 94.9% 96.7% 1.35 0.86–2.10
11–20mm 1128 571 11 16 557 5 25 95.5% 94.6% 0.99 0.71–1.37
>20mm 366 176 2 18 190 3 20 88.5% 88.2% 1.22 0.80–1.80
Tumour grade Grade 1 or 2 1797 914 17 25 914 7 39 94.9% 96.7% 1.08 0.83–1.40
Grade 3 443 226 7 17 217 4 17 90.1% 91.1% 1.26 0.82–1.94
ER status ER+ 2035 1005 15 35 1030 9 46 94.9% 94.7% 1.12 0.87–1.42
ER− 207 114 8 6 105 2 10 89.2% 87.7% 0.95 0.55–1.65
PgR status PgR+ 1816 895 13 29 921 9 40 95.1% 94.7% 1.09 0.84–1.41
PgR− 413 220 10 12 193 2 16 90.7% 90.9% 1.08 0.69–1.70
HER2 status HER2− 1845 920 19 35 925 8 39 94.2% 95.0% 1.12 0.87–1.44
HER2+ 320 156 3 6 164 3 16 94.0% 88.7% 1.36 0.81–2.27
Lymph
node status
LN− 1765 872 20 27 893 9 42 94.4% 94.4% 1.14 0.88–1.46
LN+ 488 254 4 15 234 2 14 93.0% 93.2% 1.07 0.68–1.70
Overall All patients 2298 1140 24 42 1158 11 56 94.2% 94.2% 1.13 0.91–1.41
LR local recurrence.
The hazard ratio for local recurrence-free survival is given for the whole follow-up period and shows that in every subgroup, there was no significant difference
in local control (i.e., the probability remaining local recurrence-free) between TARGIT-IORT and EBRT, and 95% CI of the hazard ratio for local recurrence-free
survival crossed 1.0, as represented in Fig. 1.
Patients in whom the specific pathological detail was not known were, —for local recurrence: one in each arm for tumour size, in TARGIT-IORT arm 1 ER/PgR
status, 2 HER status and, —for death: one in EBRT arm for tumour size, one in TARGIT-IORT arm for ER/PgR/HER2 status.
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hypothetical patient—this way best illustrates the concept—how
a combination of factors influence the decision. Two example
cases are illustrated in Supplementary Fig. 2. In order to achieve
results similar to those achieved within the trial, clinicians would
want to emulate the way the risk-adapted approach was used
within the trial. This interactive tool gives the probability of any
individual patient’s receipt of supplemental EBRT if they had
participated in the TARGIT-A trial. Using this information could
facilitate an informed decision about recommending supplemen-
tal EBRT for an individual patient.
Finally, an exploratory analysis sought an explanation for the
difference in non-breast cancer mortality that was found in the
main analysis between the two randomised arms (HR 0.59
(0.40–0.86), P= 0.005). The numbers of non-breast cancer deaths
in those who were randomised to TARGIT were 45/1140 (6/241
amongst those who received additional EBRT and 39/899 amongst
the others), and 74/1158 amongst those randomised to EBRT.
Most of this difference (79% of the difference in the number of
deaths) was contributed to by differences in deaths from
pulmonary, cardiovascular causes and other cancers. Two of the
major risks for these conditions, age and body mass index, were
equally distributed in the two randomised arms (Supplementary
Table 2, top). Of the 1140 patients randomised to TARGIT-IORT,
241 patients were deemed to have a higher risk of relapse of
breast cancer by the treating multidisciplinary team and therefore
were selected to receive supplemental EBRT. While this group
would have a higher risk of death from breast cancer, they should
not have an increased risk of death from non-breast cancer causes
—this was corroborated by the well-balanced distribution of two
recorded risk factors (age and BMI, Supplementary Table 2,
bottom). We found that patients who had TARGIT-IORT plus EBRT
(n= 241) had a statistically significant reduction in non-breast
cancer mortality (HR 0.38 (95% CI 0.17–0.88), P= 0.009) when
compared with those randomised to EBRT (n= 1158), in addition
to the significant difference seen in the remaining 899 patients
(HR 0.65 (95% CI 0.44–0.96), P= 0.0265) (Fig. 4).
DISCUSSION
The long-term results of the TARGIT-A trial9 have shown that there
was no statistically significant difference between EBRT and the
approach of risk-adapted TARGIT-IORT during lumpectomy, for
local recurrence-free survival, invasive local recurrence-free
survival, mastectomy-free survival, distant disease-free survival or
breast cancer mortality. The mortality from other causes was
significantly lower in the TARGIT-IORT arm.
In this paper, we found that the results remain the same for
each of the tumour subgroups such that no particular subgroup
fares better or worse in terms of the difference in local recurrence-
free survival for TARGIT-IORT vs. EBRT. This finding could make it
Forest plot of outcome in subgroups
Hazard ratio of local recurrence-free survival and 95% confidence interval
Forest plot of outcome in subgroups
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Fig. 1 Forest plot showing local recurrence-free survival and overall survival as per tumour subgroups. Each box represents the amount of
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Fig. 2 Subgroup analysis: overall survival in those with grade 1 or 2, n= 1797, and those with grade 3 cancers, n= 443. In total, 80% of
the patients had grade 1 or 2 cancers. Of those with grade 1 or 2 cancers vs. grade 3 cancers, 20 vs. 30% were node-positive, and 4 vs. 29%
were ER-negative, respectively. There was no difference in the rate of additional EBRT given after TARGIT-IORT between these groups.
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easier for clinicians to select patients. In order to be eligible for
risk-adapted TARGIT-IORT, patients simply need to fulfil the
eligibility criteria for the TARGIT-A trial (≥45 years of age with
invasive ductal carcinoma ≤3.5 cm in size and cN0–N1 and
suitable for breast conservation). Once the final histopathology is
available postoperatively, the interactive tool based on our
regression model could facilitate decision-making about the need
for supplemental EBRT: a clinician can input values for character-
istics for an individual patient and their tumour in this web-based
tool (https://targit.org.uk/addrt), and its output will show the
probability that that patient would have received supplemental
EBRT after TARGIT-IORT within the TARGIT-A trial. This can help the
clinician to make an individualised decision for their patient so
that the outcome would be similar to that achieved within the
TARGIT-A trial.
An important point that traditionally causes concern is the long-
term prognosis of a patient with a local recurrence. A local
recurrence has been generally regarded as a harbinger of early
death. This idea is supported by the results of the meta-analysis of
breast-conserving surgery and whole-breast external beam radio-
therapy by the Early Breast Cancer Trialists Collaborative Group,13
which determined that for every four additional women who had
a local recurrence one died from their disease. Consistent with this
long-held belief, the analysis in the TARGIT-A trial presented in this
paper also found that a local recurrence after EBRT was indeed a
powerful predictor of distant metastases, breast cancer mortality
and overall mortality. In contrast, a local recurrence after TARGIT-
IORT did not have any impact on distant metastases, breast cancer
mortality and overall mortality (Fig. 3). We recognise that the
number of events is small, but the statistical significance of this
finding is very high (P= 0.003). This remarkable finding suggests
that local recurrences after TARGIT-IORT are not indicative of the
expected poor prognosis that is seen with local recurrences after
whole-breast external beam radiotherapy. Possible explanations
for this important observation need further research, but some
suggestions about its mechanisms are the following:
A simple explanation might be that majority of local recurrences
after TARGIT-IORT are new primaries that normally do not have a
poor prognosis while EBRT may be suppressing these good-
prognosis cancers. The corroboration of this idea is seen in the
much higher DCIS: Invasive ratio (12:32 vs. 1:19) in the TARGIT-
IORT arm compared with EBRT, raising the possibility of over-
diagnosis and ascertainment bias because of potentially more
frequent use of mammography in those randomised to TARGIT-
IORT. This may have led to a higher chance of detection of DCIS or
invasive cancers that may not have progressed. However, this
detection of such good-prognosis cancers in the TARGIT-IORT arm
did not cause any reduction in mastectomy-free survival. We
might also speculate that after EBRT, a local recurrence has only
very aggressive cells that are a marker of incurable distant disease
or consist of metastatic cells that grow in the tumour supportive
wound environment. TARGIT-IORT appears to favourably influence
wound fluid composition, and this may be a mechanism by which
it might have unique radiobiology that somehow mainly allows
100%
P  value for interaction with local recurrence P  = 0.008
P  value for interaction with local recurrence P  = 0.020
Hazard of distant metastasis
P  value for interaction with local recurrence P  = 0.003
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Fig. 3 TARGIT-IORT vs EBRT: Contrasting long-term outcome after local recurrence. The hazard of distant metastasis (top left), breast
cancer death (top right) and any death (bottom) —interaction with local recurrence as a time-dependent covariate. The hazards of patients
who have local recurrence after EBRT as shown by the rising red line in each graph are significantly higher than those who have local
recurrence after TARGIT-IORT, which in turn are the same as those without any local recurrence. Please note that these figures denote
cumulative hazards of each interaction groups, whereas the curves in Fig. 4 are Kaplan–Meier estimates of cumulative incidences.
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Table 2. Total number of patients, total numbers in each arm and proportion of patients receiving supplemental EBRT among those randomised to
receive TARGIT-IORT.
Allocated TARGIT-IORT Allocated EBRT


















Overall 2298 1140 241 899 1158
Age (years)
≤50 216 117 24 93 20.5% 99
51–60 737 362 81 281 22.4% 375
61–70 1005 481 100 381 20.8% 524
>70 340 180 36 144 20.0% 160
Tumour size
≤10mm 739 369 58 311 15.7% 370
11–20mm 1128 571 121 450 21.2% 557
>20mm 366 176 59 117 33.5% 190
Grade
Grade 1 561 275 42 233 15.3% 286
Grade 2 1236 621 148 473 23.8% 615
Grade 3 443 226 50 176 22.1% 217
Margins
Negative 2000 1007 191 816 19.0% 993
Positive 252 119 49 70 41.2% 133
Invasive lobular carcinoma at final histology
Negative 2112 1053 208 845 19.8% 1059
Positive 120 58 30 28 51.7% 62
Lymphovascular invasion
Absent 1877 931 172 759 18.5% 946
Present 357 185 63 122 34.1% 172
Nodal status
Negative 1765 872 147 725 16.9% 893
1–3 nodes 418 213 76 137 35.7% 205
4 or more 70 41 17 24 41.5% 29
ER status
Positive 2035 1005 218 787 21.7% 1030
Negative 207 114 20 94 17.5% 93
PgR status
Positive 1816 895 191 704 21.3% 921
Negative 413 220 47 173 21.4% 193
HER2 status
Positive 320 156 41 115 26.3% 164
Negative 1845 920 188 732 20.4% 925
Method of presentation
Screen-detected 1494 739 148 591 20.0% 755
Symptomatic 719 364 86 278 23.6% 355
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the expression of local recurrences that are curable by earlier
surgery and change of systemic (usually endocrine) therapy.
By corollary, one might argue that avoiding radiotherapy
altogether might have even enhanced such effect—but rando-
mised evidence tells us that it does not—in trials of EBRT vs. no
EBRT, for every four local recurrences that occur in the absence of
EBRT there is one additional death13. So TARGIT-IORT may be
stopping the growth of local recurrences that have the potential
to spread and cause death, whilst allowing those local recurrences
that are a marker of curable distant disease to grow and raise an
early flag just like the canary in the coal mine. Further research
comparing the molecular characteristics of local recurrences
between the two arms of the trial could give more insight into
the biological nature of these recurrences.
The other striking outcome in the trial was that there was a
significant reduction in non-breast cancer mortality in patients
randomised to TARGIT-IORT. Now, within those randomised to
TARGIT-IORT, there were some patients (n= 241) who also had
received supplemental EBRT because they had a higher risk of
breast cancer relapse. However, their risk of non-breast cancer
death should not be any different from those who were
randomised to EBRT. Surprisingly, there was a statistically
significant difference in non-breast cancer mortality (HR 2.62
(1.14–6.04), P= 0.0093) between them, and those allocated to
EBRT. As both these groups received EBRT, the reduction in non-
breast cancer mortality cannot be attributed to the absence of
EBRT, but rather must be attributed to the presence of TARGIT-
IORT. There is however one caveat—40% of those in the EBRT arm
also received a tumour-bed boost (reminding us that TARGIT-A
was a medium-risk cohort), so this higher dose may have
contributed to the effect. In any case, the baseline major risk
factors for these deaths (age and BMI) were well balanced
between these non-randomised groups (Supplementary Table 1).
This long-term outcome is consistent with previous reports and
prompts the hypothesis that a single large dose of radiation such
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have an abscopal effect, i.e., an effect away from the site of
irradiation, by influencing the tumour microenvironment or by
immunological mechanisms.14–27,28 Strange as it may seem, such
an abscopal effect appears to give long-term protection against
deaths from cardiovascular causes and other cancers. The early
separation of lines in the K–M curves that starts soon after
randomisation also suggests such a ‘drug-like’ effect, while a
separation starting a few years later in the comparison of TARGIT-
IORT alone vs. EBRT suggests an effect of avoiding EBRT (Fig. 4).
We believe that for the effect of immediate TARGIT-IORT on
wound fluid, and its potential abscopal effects, the temporal
proximity of TARGIT-IORT to surgery is crucially important. This
TARGIT-IORT delivery to the fresh tumour bed immediately after
lumpectomy, without any additional trauma, did not happen in
the delayed IORT trial.29 The IORT in the experimental arm in that
separate study29 was delivered at a median of 37 days post-
operatively, by re-opening the wound. This difference in timing of
radiotherapy may well offer an explanation for the difference in
non-breast cancer mortality outcomes. Of course, we need to
recognise that these data only generate the hypothesis, and do
not prove an abscopal effect. The TARGIT-B superiority trial, in
which patients are being recruited from 38 centres in 15 countries,
is comparing TARGIT-IORT boost during lumpectomy, in addition
to post-operative whole-breast radiotherapy, vs. conventional
EBRT (i.e., TARGIT-IORT+ EBRT vs. EBRT). It will provide rando-
mised data to assess such putative abscopal effects.
In conclusion, these long-term data from the TARGIT-A trial
show that for every subgroup of patients with breast cancer who
meet our trial selection criteria, risk-adapted single-dose TARGIT-
IORT during lumpectomy is an effective and safe alternative to
several weeks’ course of post-operative EBRT. The observation that
local recurrence after TARGIT-IORT, unlike after EBRT, does not
have a poor prognosis is reassuring. The potential beneficial effect
of TARGIT-IORT during surgery on non-breast cancer mortality
seen in this trial has increased the importance of forthcoming
randomised data on non-breast cancer mortality from the TARGIT-
B trial.
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